Free Trial

BioCryst Pharmaceuticals (BCRX) News Today

BioCryst Pharmaceuticals logo
$10.29 -0.08 (-0.77%)
Closing price 04:00 PM Eastern
Extended Trading
$10.20 -0.08 (-0.83%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCRX Latest News

ORLADEYO® (berotralstat) Approved in Colombia
Cantor Fitzgerald Estimates BCRX FY2026 Earnings
BioCryst Pharmaceuticals, Inc. stock logo
Cantor Fitzgerald Weighs in on BCRX FY2026 Earnings
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates t
BioCryst Pharmaceuticals, Inc. stock logo
Mackenzie Financial Corp Acquires 55,535 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Mackenzie Financial Corp lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 190.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,662 shares
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 1-Year High - Still a Buy?
BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month High - Here's What Happened
BioCryst Pharmaceuticals, Inc. stock logo
Millennium Management LLC Trims Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Millennium Management LLC lessened its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 44.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 790,105 shares of the biot
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Rating of "Moderate Buy" from Brokerages
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight
BioCryst Pharmaceuticals, Inc. stock logo
Bank of America Corp DE Sells 261,127 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Bank of America Corp DE lowered its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 22.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 899,838 shares of the biotechnology company's
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Reduced by Voloridge Investment Management LLC
Voloridge Investment Management LLC trimmed its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 11.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,579,960 shares of the biotechnology com
BioCryst Pharmaceuticals, Inc. stock logo
Woodline Partners LP Makes New $3.39 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Woodline Partners LP acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 450,199 shares of the biotechnology company's stock, valued at approximately $3,385,000. Woodline
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Man Group plc
Man Group plc increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 46.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,954 shares of the biotechnology company's stock
BioCryst Pharmaceuticals, Inc. stock logo
Nuveen Asset Management LLC Sells 1,395,503 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Nuveen Asset Management LLC lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 29.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,419,046 shares of the biot
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Raised by Two Sigma Advisers LP
Two Sigma Advisers LP boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 14.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,499,812 shares of the biotechnology company's sto
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded by StockNews.com to Strong-Buy Rating
StockNews.com raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday.
BioCryst Pharmaceuticals, Inc. stock logo
Rafferty Asset Management LLC Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Rafferty Asset Management LLC trimmed its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 36.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 234,836 shares of the biotechnology com
BioCryst Pharmaceuticals, Inc. stock logo
D. E. Shaw & Co. Inc. Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
D. E. Shaw & Co. Inc. raised its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 37.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 315,263 shares of the biotechnology compan
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stake Boosted by Lazard Asset Management LLC
Lazard Asset Management LLC increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 68.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,516 shares of the biotechnolog
BioCryst Pharmaceuticals, Inc. stock logo
Deutsche Bank AG Purchases 58,687 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Deutsche Bank AG boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 519,217 shares of the biotechnology compan
BioCryst Pharmaceuticals, Inc. stock logo
BNP Paribas Financial Markets Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BNP Paribas Financial Markets lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 60.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 196,225 shares of the biotechnology company's stock after selling 300
BioCryst Pharmaceuticals, Inc. stock logo
Ameriprise Financial Inc. Sells 51,920 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Ameriprise Financial Inc. decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,720,581 shares of the biotechnology company's stock after selling 5
BioCryst Pharmaceuticals, Inc. stock logo
Jacobs Levy Equity Management Inc. Sells 119,719 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Jacobs Levy Equity Management Inc. lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 32.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 247,795 shares of the biotechnology company's stock
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Northern Trust Corp
Northern Trust Corp boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,004,911 shares of the biotechnology company's st
BioCryst Pharmaceuticals, Inc. stock logo
Graham Capital Management L.P. Invests $731,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Graham Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 97,257 shares of the biotechnology company's stock, valu
BioCryst Pharmaceuticals, Inc. stock logo
The Manufacturers Life Insurance Company Sells 195,621 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
The Manufacturers Life Insurance Company decreased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 65.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 103,531 shares of the biotechnology company's
BioCryst Pharmaceuticals, Inc. stock logo
Parkman Healthcare Partners LLC Sells 247,167 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Parkman Healthcare Partners LLC cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 53.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 216,881 shares of the biotechno
BioCryst Pharmaceuticals, Inc. stock logo
Balyasny Asset Management L.P. Purchases Shares of 529,653 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Balyasny Asset Management L.P. acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 529,653 shares of the biotechnology company's stock, valued at approximately $3,983
BioCryst Pharmaceuticals, Inc. stock logo
Price T Rowe Associates Inc. MD Cuts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Price T Rowe Associates Inc. MD cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 94.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 126,806 shares of the biotechnology company's
BioCryst Pharmaceuticals, Inc. stock logo
Bayesian Capital Management LP Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Bayesian Capital Management LP bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,700 shares of the biotechnology co
BioCryst Pharmaceuticals, Inc. stock logo
BCRX FY2025 EPS Forecast Lifted by Cantor Fitzgerald
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for BioCryst Pharmaceuticals in a report released on Tuesday, May 6th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnolo
BioCryst Pharmaceuticals, Inc. stock logo
HC Wainwright Has Optimistic Outlook of BCRX Q2 Earnings
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - HC Wainwright increased their Q2 2025 EPS estimates for shares of BioCryst Pharmaceuticals in a research note issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $0.10 per share
BioCryst Pharmaceuticals, Inc. stock logo
Wedbush Issues Positive Estimate for BCRX Earnings
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Wedbush raised their Q2 2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a note issued to investors on Monday, May 5th. Wedbush analyst L. Chico now anticipates that the bio
BioCryst Pharmaceuticals, Inc. stock logo
AQR Capital Management LLC Buys 52,047 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
AQR Capital Management LLC raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 6.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 839,274 shares of the biotechnology company's stock after purchasing an
BioCryst Pharmaceuticals, Inc. stock logo
Tudor Investment Corp ET AL Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Tudor Investment Corp ET AL bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 99,450 shares of the biotechnology compan
BioCryst Pharmaceuticals, Inc. stock logo
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $11.00
Barclays boosted their target price on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Wednesday.
BioCryst Pharmaceuticals, Inc. stock logo
HC Wainwright Has Positive Outlook for BCRX FY2029 Earnings
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Research analysts at HC Wainwright boosted their FY2029 earnings per share estimates for BioCryst Pharmaceuticals in a research report issued on Tuesday, May 6th. HC Wainwright analyst A. Fein now anticipates that the biotechnology comp
BioCryst Pharmaceuticals, Inc. stock logo
Research Analysts Set Expectations for BCRX Q3 Earnings
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities researchers at Wedbush boosted their Q3 2025 EPS estimates for shares of BioCryst Pharmaceuticals in a report released on Monday, May 5th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings
BioCryst Pharmaceuticals, Inc. stock logo
Schonfeld Strategic Advisors LLC Grows Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Schonfeld Strategic Advisors LLC increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 27.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 217,740 shares of the bi
Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

BCRX Media Mentions By Week

BCRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCRX
News Sentiment

1.20

0.90

Average
Medical
News Sentiment

BCRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCRX Articles
This Week

9

7

BCRX Articles
Average Week

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BCRX) was last updated on 6/16/2025 by MarketBeat.com Staff
From Our Partners